Mutations in the BRCA1 gene are one of the most common risk factors for breast and ovarian cancers. Although tumors that harbor BRCA1 mutations initially respond well to cancer treatments, many tumors eventually become less ...
Jul 25, 2016
0
82
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of ...
Jun 16, 2016
0
1
Many cancer therapies function by activating proteins like Caspase-3 (CASP3) that promote cell death. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the ...
Aug 27, 2013
0
0
University of Southampton biological scientists are leading a major research project aimed at making drugs more effective.
Mar 27, 2013
0
0
Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens.
Jan 23, 2013
0
0
The American Society of Clinical Oncology (ASCO) has just released its annual report on the top cancer advances of the year. Clinical Cancer Advances 2012: ASCO's Annual Report on Progress Against Cancer, highlights major ...
Dec 3, 2012
0
0
(AP)—More than five years after a radical treatment, a San Francisco man and his German doctor are convinced that he remains the first person cured of infection with HIV, the virus that causes AIDS.
Sep 12, 2012
0
0
Oncolytic virology uses live viruses to sense the genetic difference between a tumor and normal cell. Once the virus finds a tumor cell, it replicates inside that cell, kills it and then spreads to adjacent tumor cells to ...
Oct 18, 2011
0
0
